Post job

Impel NeuroPharma overview

Industry
Biotechnology
Revenue
Headquarters
Employees
74
Founded in
Website
Organization type
Public
Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. The company was founded in 2008 and is headquartered in Seattle, Washington.
Based in Seattle, WA, Impel NeuroPharma is a small health care company with only 74 employees and an annual revenue of $12.7M.

Impel NeuroPharma's mission statement

To create and provide transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the CNS.

In demand companies are hiring! Let Zippi apply for you!

Floating question marks illustration
-

Impel NeuroPharma employee reviews

Be the first to review!

Do you work at Impel NeuroPharma?

Help job seekers learn about working at Impel NeuroPharma

On this page

Be the first to review Impel NeuroPharma

Anonymously rate your employee experience

Your opinion can help other job seekers

Do you like working at Impel NeuroPharma?

The team at Impel NeuroPharma

  • The founders of Impel NeuroPharma are John D. Hoekman, Michael Hite and Rodney Ho.
  • The key people at Impel NeuroPharma are John D. Hoekman, Michael Hite and Rodney Ho.
Key people
John D. Hoekman
Michael Hite
Rodney Ho

Impel NeuroPharma rankings

Impel NeuroPharma is ranked #83 on the Best Health Care companies to work for in Washington list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.

Read more about how we rank companies.

Impel NeuroPharma salaries

Average Impel NeuroPharma salary
$44,841
yearly
$21.56 hourly
Updated March 14, 2024

Rate Impel NeuroPharma's commitment to diversity and inclusion.

Zippia waving zebra

Do you work at Impel NeuroPharma?

Does Impel NeuroPharma actively promote diversity and inclusion?

Impel NeuroPharma financial performance

9.1
Performance score

We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.

Impel NeuroPharma currently has 12.7M in revenue. Impel NeuroPharma's most recent quarter produced 6.6m (q2'2023).

Impel NeuroPharma annual revenue

$13M
$10M
$8M
$5M
$3M
$0
2021
2022

Are you an executive, HR leader, or brand manager at Impel NeuroPharma?

Claiming and updating your company profile on Zippia is free and easy.

Impel NeuroPharma FAQs

Search for jobs

Zippia gives an in-depth look into the details of Impel NeuroPharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Impel NeuroPharma. The employee data is based on information from people who have self-reported their past or current employments at Impel NeuroPharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Impel NeuroPharma. The data presented on this page does not represent the view of Impel NeuroPharma and its employees or that of Zippia.

Impel NeuroPharma may also be known as or be related to IMPEL NEUROPHARMA INC, Impel NeuroPharma, Impel NeuroPharma, Inc., Impel Neuropharma, Impel Neuropharma, Inc. and Impel Pharmaceuticals Inc.